Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Building on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we initiated a trial of combined pentostatin (2 mg/m(2)), cyclophosphamide (600 mg/m(2)), and rituximab (375 mg/m(2)) for 65 symptomatic, previously untreated patients. Of 64 evaluable patients, 34 (53%) were hig...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kay, Neil E., Geyer, Susan M., Call, Timothy G., Shanafelt, Tait D., Zent, Clive S., Jelinek, Diane F., Tschumper, Renee, Bone, Nancy D., Dewald, Gordon W., Lin, Thomas S., Heerema, Nyla A., Smith, Lisa, Grever, Michael R., Byrd, John C.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2007
Pynciau:
Plenary Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785105/
https://ncbi.nlm.nih.gov/pubmed/17008537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-07-033274
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg